CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 60 enrolled
Drug / intervention
Insulin +1 moredrug
Likely dose
Insulin 140 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01643382
NCT01643382N/ACompleted
CompareCT.gov

Randomized Study of the Impact of Peri-operative Glucose Control on Short Term Renal Allograft Function After Transplantation

University of California, San Francisco·interventional·Posted Jul 18, 2012·Updated Nov 5, 2020

In Brief

A clinical study evaluating Insulin and Insulin, Asp(B28)- for Diabetes and End Stage Renal Disease. Completed, enrolled 60 participants across 1 site.

Detailed Summary

Based on multiple prior studies, kidney transplant recipients with diabetes are at higher risk for poor initial graft function after transplant. Our study is designed to determine if tight blood sugar control around the time of kidney transplant will improve short term graft function.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, End Stage Renal Disease
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJul 18, 2012
Enrollment StartAug 1, 2012
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 14.0 years ago

Interventions

Insulindrug

Insulin will be given in a continuous low dose infusion. The infusion will be adjusted based on the patient's blood sugar with the goal of keeping the level between 100-140 mg/dL

Insulin, Asp(B28)-drug

Insulin will be given through subcutaneous injection every few hours based on the patient's blood sugar level.